What is Neurocrine Biosciences's R&D?

Neurocrine Biosciences (NBIX) reported R&D of $296.2M in Q1 2026.

How has Neurocrine Biosciences's R&D changed year-over-year?

Neurocrine Biosciences's R&D increased by 12.5% year-over-year, from $263.2M to $296.2M.

What is the long-term trend for Neurocrine Biosciences's R&D?

Over 4 years (2021 to 2025), Neurocrine Biosciences's R&D has grown at a 32.6% compound annual growth rate (CAGR), from $328.1M to $1.02B.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Neurocrine Biosciences NBIX R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

Acadia PharmaceuticalsACAD

$76.87M-1.8%

CRN

CRNXCRNX

$100.08M+31.3%

Solid Biosciences Inc.SLDB

$46.14M+49.3%

MapLight Therapeutics, Inc. MPLT

$53.68M+171%

BridgeBio PharmaBBIO

$126.64M+13.6%

Segments

By segment

See full

Reportable Segment$296.2M+12.5%

Other financials

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation

See full

Market cap$17.3B+29.6%

Enterprise value$17.49B+28.9%

P/E25.9×-12.5×

P/S5.6×+0.3×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's R&D?: Neurocrine Biosciences (NBIX) reported R&D of $296.2M in Q1 2026.
How has Neurocrine Biosciences's R&D changed year-over-year?: Neurocrine Biosciences's R&D increased by 12.5% year-over-year, from $263.2M to $296.2M.
What is the long-term trend for Neurocrine Biosciences's R&D?: Over 4 years (2021 to 2025), Neurocrine Biosciences's R&D has grown at a 32.6% compound annual growth rate (CAGR), from $328.1M to $1.02B.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.